home.aspx

 
.

UTILIZATION OF MODULAR MANUFACTURING TO ENHANCE/UPSCALE CAPACITY DURING COVID-19

September 23, 2020 | (11:00 AM)
USA (United States of America)
SHARESHARESHARE
The COVID-19 pandemic is pushing our industry to accelerate the development and supply of vaccines and treatments at a rate never seen before. The use of a pre-fabricated modular approach to designing and constructing cGMP manufacturing using autonomous cleanroom can be an effective approach at meeting these new challenges. The benefits and value of modular manufacturing can only be achieved through a partnership with regulators. The U.S. FDA has discussed the use of prefabricated modular manufacturing with industry stakeholders prior to the pandemic and will discuss how this technology may enable the rapid increases in capacity needed as a result of this global event.